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AbstrACt
Introduction Multimorbidity and polypharmacy are 
important risk factors for drug-related hospital admissions 
(DRAs). DRAs are often linked to prescribing problems 
(overprescribing and underprescribing), as well as non-
adherence with drug regimens for different reasons. In this 
trial, we aim to assess whether a structured medication 
review compared with standard care can reduce DRAs in 
multimorbid older patients with polypharmacy.
Methods and analysis OPtimising thERapy to prevent 
Avoidable hospital admissions in Multimorbid older people 
is a European multicentre, cluster randomised, controlled 
trial. Hospitalised patients ≥70 years with ≥3 chronic 
medical conditions and concurrent use of ≥5 chronic 
medications are included in the four participating study 
centres of Bern (Switzerland), Utrecht (The Netherlands), 
Brussels (Belgium) and Cork (Ireland). Patients treated 
by the same prescribing physician constitute a cluster, 
and clusters are randomised 1:1 to either standard care 
or Systematic Tool to Reduce Inappropriate Prescribing 
(STRIP) intervention with the help of a clinical decision 
support system, the STRIP Assistant. STRIP is a structured 
method performing customised medication reviews, 
based on Screening Tool of Older People’s Prescriptions/
Screening  Tool to Alert to Right Treatment criteria to 
detect potentially inappropriate prescribing. The primary 
endpoint is any DRA where the main reason or a 
contributory reason for the patient’s admission is caused 
by overtreatment or undertreatment, and/or inappropriate 
treatment. Secondary endpoints include number of any 
hospitalisations, all-cause mortality, number of falls, 
quality of life, degree of polypharmacy, activities of daily 
living, patient’s drug compliance, the number of significant 
drug–drug interactions, drug overuse and underuse and 
potentially inappropriate medication.
Ethics and dissemination The local Ethics Committees 
in Switzerland, Ireland, The Netherlands and Belgium 
approved this trial protocol. We will publish the results of 
this trial in a peer-reviewed journal.
Main funding European Union's Horizon 2020 
programme.
trial registration number NCT02986425, 
SNCTP000002183, NTR6012, U1111-1181-9400.
IntroduCtIon
Patients with multimorbidity have been 
excluded in >60% of the randomised 
controlled trials (RCTs) published in high-im-
pact journals during the last 15 years due to 
strengths and limitations of this study
 ► This is the first multicentre randomised trial that ex-
amines the impact of a structured approach to opti-
mise pharmacotherapy in multimorbid older people 
on drug-related hospital admissions.
 ► This is one of the largest trials undertaken in the 
growing population of multimorbid older adults; a 
population, that is, to date poorly investigated and 
often excluded from large scale trials.
 ► We chose a cluster randomisation design in order 
to limit potential contamination from a learning ef-
fect among the prescribing physicians; however, the 
cluster design of this trial entails some potential for 
selection bias.
 ► A blinded adjudication committee (pharmacist and 
senior physician) for each site will judge whether a 
hospital admission during follow-up should be con-
sidered a drug-related hospital admission.
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their complexity and frailty.1 This finding is in contrast to 
the rapidly growing numbers of patients with coexisting 
chronic diseases, with associated increased mortality,2 
decreased health-related quality of life (QoL), increased 
healthcare utilisation, increased hospital admissions3 4 
and higher rates of drug prescriptions with subsequent 
polypharmacy.5 Polypharmacy refers to the concurrent 
use of multiple drugs, often defined as taking ≥5 long-
term medications.6 Appropriate polypharmacy can 
improve health-related QoL and prevent consequences 
of diseases, whereas inappropriate polypharmacy is often 
harmful, particularly in multimorbid older people.6 Poly-
pharmacy increases the risk of inappropriate prescribing, 
defined as misuse of medication or overtreatment and 
drug–drug interactions.7–9 With polypharmacy, there is 
also an increased risk of non-compliance, adverse drug 
reactions (ADRs), drug–drug and drug–disease interac-
tions.10 Inappropriate prescribing can lead to a drug-re-
lated hospital admission (DRA),11 lower QoL and a 
higher number of falls.12 13 The incidence of DRAs in 
older people may be as high as 30% of all hospital admis-
sions,13–15 and about half of DRAs are considered poten-
tially preventable.13 16 
Literature reviews recently suggested that interventions 
optimising polypharmacy could reduce inappropriate 
prescribing17 18 and the risk of ADRs.19 The Screening 
Tool of Older People’s Prescriptions/Screening Tool 
to Alert to Right Treatment (STOPP/START) criteria20 
have been developed by geriatric medicine and phar-
macotherapy experts based on review of up-to-date 
evidence and consensus validation to screen for inap-
propriate prescribing; they have also been shown to 
significantly improve medication appropriateness.21 
This property of STOPP/START criteria therefore, has 
the potential to reduce DRAs.22 The Systematic Tool to 
Reduce Inappropriate Prescribing (STRIP) is a tool that 
combines STOPP/START criteria to increase appropriate 
prescribing for older people.23 However, until now, only 
a few RCTs have examined the impact of reducing inap-
propriate medications on clinical outcomes and they had 
several limitations, such as missing adjudication of DRAs 
by an independent adjudication committee, no cluster 
randomisation (contamination bias) or small sample size, 
young population and/or short follow-up time, leaving 
currently considerable uncertainty on the best ways to 
improve the appropriate use of polypharmacy.14 24 25
The OPtimising thERapy to prevent Avoidable hospital 
admissions in Multimorbid older people (OPERAM) trial 
will examine the effect of a structured medication review 
(STRIP) supported by the STRIP Assistant (STRIPA) clin-
ical decision support software on DRAs (main endpoint) 
compared with usual care. Secondary endpoints include 
number of any hospitalisations, all-cause mortality, 
number of falls, QoL, degree of polypharmacy, activi-
ties of daily living (ADL), patient’s drug compliance, as 
well as the number of significant drug–drug interactions, 
drug overuse and underuse and potentially inappropriate 
medication.
MEthods And AnAlysIs
General study design and setting
OPERAM is a European multicentre cluster RCT. A 
prescribing physician will define a cluster. Older hospi-
talised patients with multimorbidity and polypharmacy 
will receive either a structured drug review or usual 
care, according to the allocation of their prescribing 
physician. Clusters will be randomised 1:1 to either the 
intervention arm (drug review) or usual care. Patients 
will be followed-up by phone at 2, 6 and 12 months after 
inclusion; information may be provided by proxy persons 
(table 1).
Table 1 Study population, intervention, control and outcomes
Population Consecutive older adults (≥70 years) with multimorbidity (≥3 chronic medical problems) and polypharmacy 
(≥5 regular drugs for >30 days).
Intervention Pharmacotherapy optimisation based on the Systematic Tool to Reduce Inappropriate Prescribing through (1) 
systematic medication review by a physician and a pharmacist, with support of the STRIP Assistant, a software-based 
tool taking into account the predictable adverse medication effects, advising safe and appropriate therapy using 
established STOPP/START criteria, monitoring clinically relevant interactions and dosing appropriately in accordance 
with renal function, (2) drug discussion and adaptation with the prescribing physician, (3) shared decision-making with 
the patient and (4) generation of a report with specific recommendations for the patient’s general practitioner.
Control Usual practice and a sham intervention using a questionnaire (Medication Adherence Measure Questionnaire, 
©MMAS30–32*) by a team member (the physician or the pharmacist) to mimic the intervention and improve blinding of 
the patient and other blinded team members.
Outcomes Primary: drug-related hospital admission within 1 year after enrolment
Secondary: number of any hospitalisations, mortality, number of falls, quality of life, degree of polypharmacy, activities 
of daily living, patient’s drug compliance, as well as the number of significant drug–drug interactions, drug overuse 
and underuse and potentially inappropriate medication.
*Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A licence agreement is available from: Donald 
E Morisky, ScD, ScM, MSPH, Professor, Department of Community Health Sciences, UCLA Fielding School of Public Health, 650 
Charles E. Young Drive South, Los Angeles, CA 90 095–1772, dmorisky@ucla.edu.
START/STOPP, Screening Tool of Older People’s Prescriptions/Screening Tool to Alert to Right Treatment.
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This study protocol follows the Standard Protocol Items: 
Recommendations for Interventional Trials guidelines.26
objective
This study aims to compare the effect of a structured 
medication review (supported by the STRIPA software) 
versus usual care on DRAs. Secondary endpoints include 
number of any hospitalisations, mortality, number of falls, 
QoL, degree of polypharmacy, ADL, all-cause mortality, 
patient’s drug compliance, as well as the number of 
significant drug–drug interactions, drug overuse and 
any rehospitalisation occurring within 1 year after the 
index-hospitalisation, underuse and potentially inappro-
priate medication.
Cluster definition
The trial is conducted in four University Hospital Centres 
in Europe (Bern, Switzerland; Utrecht, The Netherlands; 
Brussels, Belgium; Cork, Ireland). Clusters are defined 
by the prescribing physician, that is, the single physician 
who has the final responsibility for the pharmacotherapy 
and treatment of patients in the department/ward and 
also decides on the implementation of potential treat-
ment suggestions made by involved specialists. Clusters 
are possible in any department/ward at each site with 
a relevant proportion of the appropriate patient popu-
lation (multimorbid older people with polypharmacy, 
see above), where patients are not included in another 
trial aiming at optimising drug therapy. Recruitment of 
potential physicians follows a multilevel approach: first, 
eligible departments/wards are identified by the local 
principal investigator and then prescribing physicians are 
enrolled in order to each form a cluster within the trial. 
Enrolment and opening of clusters is distributed over the 
complete recruitment period to ensure an approximately 
similar number of open clusters in each site at any time. 
The recruitment target ranges from a minimum of 12 to 
a maximum of 38 patients per cluster in order to achieve 
recruitment of 2000 patients.
Inclusion criteria
Consecutive patients are screened for eligibility and 
recruited from the clusters at each site. Inclusion criteria 
are age 70 years or older, multimorbidity (defined as 
three or more chronic medical conditions) and polyphar-
macy (defined as use of five or more regular drugs for 
>30 days). Written informed consent by patients them-
selves or, in the case of cognitive impairment by a legal 
representative, is required before enrolment.
Exclusion criteria
Exclusion criteria are reduced to a minimum to allow 
for maximum generalisability. Only patients planned for 
direct admission to palliative care (<24 hours after admis-
sion), or patients undergoing a structured drug review 
other than the trial intervention, or who have passed 
a structured drug review within the last 2 months are 
deemed ineligible.
randomisation
In this study design, each prescribing hospital physician 
defines a cluster. Physicians are allocated 1:1 to either the 
intervention arm or the control arm, using a probabi-
listic minimisation method implemented by a web-based 
clinical trial management system (WebSpirit hosted by 
the Clinical Trials Unit (CTU) Bern). Minimisation is 
done according to country in order to ensure a balanced 
distribution of hospitals. The minimisation algorithm is 
implemented using randomisation lists generated by an 
independent statistician in Stata (StataCorp., Stata Statis-
tical Software Version 14). Only system administrators 
who are otherwise not involved in the conduct of the trial 
have access to the randomisation lists, to ensure conceal-
ment of allocation.
blinding procedures
This study is partially blinded, with blinding implemented 
at each site as follows (table 2):
 ► Screening and enrolment. A person blinded to the 
allocation of recruiting clusters screens and enrols 
patients in order to avoid selection bias. Coded infor-
mation (gender, age, multimorbidity, degree of poly-
pharmacy and so on) from all screened patients is 
collected and regularly monitored centrally to assess 
the risk of selection bias. The blinded person works 
separately from the rest of the trial team at that site 
and all team members signed a non-disclosure form 
to limit unblinding of this person.
 ► Patients. A tailored informed consent procedure is 
implemented in which patients are given a ‘high-level 
description’ of the study objectives with only superfi-
cial information on the study intervention, as accepted 
by the ethics committees. They are informed that their 
prescribing physician is allocated to one of the study 
groups without revealing which study group it is in 
order to minimise performance and other reporting 
biases during follow-up. Patients randomised to the 
control arm undergo an attention sham intervention 
(figure 1).
 ► Prescribing physician. Similarly, the cluster-defining 
physician is not informed about his/her study arm 
allocation, receiving only a minimum amount of 
required information regarding the study objectives, 
as described above. Furthermore, each cluster-de-
fining physician signs a non-disclosure contract to 
limit unblinding.
To communicate study inclusion and results of the 
medication review to the patients’ general practitioner 
(GP), all GPs receive the same standardised high-level 
information about the study goals and a document indi-
cating that one of their patients has been included. For 
those patients in the intervention arm, the GPs addition-
ally receive a report about the recommendations from 
the intervention (STRIPA report).
 ► Follow-up. A blinded trial team member assesses 
the trigger events for the primary outcome and all 
secondary outcomes by telephone interview. In case 
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of hospital readmission, an unblinded team member 
is informed by the blinded follow-up interviewer. The 
unblinded team member then collects the necessary 
documentation and information about the hospitali-
sation and ensures any clue about the treatment allo-
cation is concealed before giving the documents to 
the adjudication board.
 ► Adjudicators. Blinded independent adjudication 
boards composed of an experienced pharmacist and 
physician at each study site adjudicate the primary 
outcome (DRA) using a standardised chart review 
method.27
Intervention
An unblinded, independent trial team composed of a 
research physician and pharmacist conducts the inter-
vention during the hospital stay of the study participant. 
All team members conducting the intervention under-
went training prior to the beginning of the study. The 
study intervention is a structured method to perform 
pharmacotherapy optimisation called STRIP. The 
STRIP intervention consists of nine steps and is admin-
istered early during the index hospitalisation. In order 
to enable healthcare providers to incorporate STRIP into 
daily practice the so-called STRIPA has been developed, 
a stand-alone web application of the STRIP. It is a soft-
ware-based tool for the support of the pharmaceutical 
analysis (step 2 of STRIP) by means of (1) taking into 
account the predictable adverse medication effects, (2) 
advising safe and appropriate therapy using established 
STOPP/START criteria,20 (3) monitoring clinically rele-
vant interactions and (4) dosing appropriately in accor-
dance with renal function. With STRIPA, the number 
of correct medical decisions during a medication review 
was significantly increased, whereas the number of inap-
propriate medication decisions was reduced.28 The nine 
steps of STRIP are as follows.
1. Structured history taking of medication using a ques-
tionnaire for taking the medication history based on 
the medication taken at home: Structured History tak-
ing of Medication use questionnaire.29
2. Recording of medications and diagnoses in the de-
cision-support software with implemented STOPP/
START criteria (STRIPA).
3. Structured medication review, including evaluation of 
STRIPA recommendations, by a qualified physician 
and pharmacist.
4. Generation of a report with specific recommendations 
for the prescribing hospital physician.
5. Communication and discussion of the structured drug 
review report with the prescribing physician, with pos-
sible adaptation of recommendations. The prescribing 
physician remains responsible for final decisions on 
drug therapy.
6. Shared decision-making with the patient to take into 
account patient preferences, again with possible adap-
tation of recommendations.
Table 2 Blinding status and measures to assure blinding
Blinding status How to achieve blinding
Recruitment team (study nurse/
research physician)
Blinded Randomisation status will be kept concealed from the recruiting team, no 
access is given to unblinded study information in the database or locally to the 
source data.
Intervention team (physician, 
pharmacist)
Unblinded In order to perform a safe intervention, including a shared decision-making with 
the patient, blinding is impossible.
Follow-up team (study nurse) Blinded Randomisation status will be kept concealed from the team conducting follow-
up calls, no access is given to unblinded study information in the database 
or locally to the source data. In case an event or serious adverse event has 
occurred, the unblinded study team will be informed.
Unblinded This team is informed about the treatment allocation. They collect the necessary 
information about events and anonymise revealing information about allocation 
on the documents for the adjudications. Make safety assessments.
Adjudication (pharmacist/
physician)
Blinded, work 
independently from 
study team
Receives only blinded information on hospital admission and deaths after study 
inclusion.
Patients Partially blinded Will be seen by the study team in case of intervention or control allocation. 
Control patients undergo a sham intervention using the ©MMAS-8.30–32
Prescribing physician Partially blinded Will receive only high-level information about the trial. Every prescribing 
physician who defines a cluster will sign a disclosure form in order not to share 
information about the approach of the study team with their colleagues.
General practitioner Partially blinded Will receive only high-level information about the trial using an information flyer 
that does not inform about the two different study arms. The GP will receive a 
form about study inclusion for each patient (regardless of study allocation), and 
in the case of the intervention group, the GP will also receive the STRIPA report.
©MMAS, Medication Adherence Measure Questionnaire; GP, general practitioner; STRIPA, STRIP Assistant.
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7. Revision based on new data acquired during hospital-
isation (eg, new diagnoses, occurrence of ADRs).
8. Generation of a report with specific recommendations 
for the patient’s GP (STRIPA report).
9. Mail delivery of the report to the GP with optional, ad-
ditional direct communication.
Control intervention (standard/routine/comparator)
Participants in the control group receive medication 
review by their prescribing physicians in accordance 
with usual practice at each site. A sham intervention is 
conducted using the Medication Adherence Measure 
Questionnaire (©MMAS-8).30–32 The ©MMAS-8 sham 
intervention is administered by the team members who 
are also conducting the intervention, to mimic the inter-
vention. This helps to maintain the blinding status of the 
patients and blinded team members.
Follow-up
Follow-up and outcome data will be gathered via tele-
phone interviews at 2, 6 and 12 months after the index 
hospitalisation. Included patients or their proxy persons 
will be interviewed by a blinded trial team member to 
assess the trigger events for the primary outcome and 
all secondary outcomes. If necessary, the treating physi-
cian of the included participant will also be contacted to 
complete the missing data.
Assessment of primary outcome
The primary patient-level outcome of this trial is the first 
DRA, that is, rehospitalisation within 1 year after enrol-
ment. Rehospitalisations are detected during the follow-up 
telephone interviews by asking the patient or proxy 
person directly about any hospital stays since discharge 
from the index hospitalisation. For all patient-reported 
rehospitalisations occurring after the initial discharge, 
detailed documentation will be requested from the 
respective hospital.
An independent and blinded adjudication committee 
(per site) composed of one physician and one pharmacist 
adjudicates the drug relatedness of each hospital admis-
sion using a standardised adjudication guideline.27 For 
each patient, reported hospitalisations are adjudicated 
consecutively until the first DRA is confirmed by the adju-
dication committee. We only consider hospitalisations 
for adjudication that are preceded by discharge from 
the hospital where the patient was enrolled in the trial 
and where the patient is managed in hospital for longer 
than 24 hours (but not hospitalisations for a diagnostic 
or elective procedure for a pre-existing condition). The 
hospital admission is assessed for its relationship with 
the medication taken by the study participant prior to 
rehospitalisation. To assess the inter-rater reliability of 
our standardised adjudication guideline to identify DRA, 
a certain amount of common cases will be evaluated by 
adjudicators from all study sites.
Assessment of secondary outcomes
We assess secondary outcomes after enrolment (to 
generate a baseline) and during the follow-up telephone 
calls.
Secondary endpoints include number of any hospital-
isations, all-cause mortality, number of falls, QoL, degree 
of polypharmacy, ADL, patient’s drug compliance, as 
well as the number of significant drug–drug interactions, 
drug overuse and underuse and potentially inappropriate 
medication.
All follow-up information is assessed via telephone call 
by a blinded trial team member at 2, 6 and 12 months 
of follow-up. In case the patient cannot be reached, 
the team member conducting the telephone interviews 
attempts to identify the patient’s survival status and collect 
the required information at any of the follow-up calls by 
contacting family members/proxies, responsible person 
from a nursing home (if applicable) or the patient’s GP.
The team member asks specifically about recent hospi-
talisations and healthcare utilisation (including unsched-
uled physician consultations and visits to the emergency 
department without hospital admission). Furthermore, 
the medication currently taken by the patient is recorded, 
as are adverse medical events including adverse drug 
events and ADRs as well as falls. If necessary (eg, if the 
Figure 1 Study flowchart (*planned numbers).
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patient does not remember his/her current medica-
tion), this information is obtained by contacting patients’ 
GPs, pharmacists, proxies or responsible persons from a 
nursing home. The degree of polypharmacy is defined as 
the number of regular chronic medications (<10 vs ≥10). 
QoL is assessed using the five dimensional EuroQOL 
(EQ-5D) instrument.33 ADL are assessed using the Barthel 
Index basic ADL questionnaire.34
Drug compliance is measured using the ©MMAS-8.30–32 
The numbers of drug–drug interactions, drug overuse and 
underuse, as well as potentially inappropriate medication 
are assessed for the intervention group at 2 months, based 
on STRIPA information including the medical diagnoses 
from the index hospitalisation and the updated medica-
tion list from the 2-month telephone follow-up. Assess-
ment of safety outcome will be based serious adverse 
events. In addition, all recorded device deficiencies will 
be described.
data management
All data will be entered electronically using a dedicated 
electronic data capturing system (WebSpirit) hosted 
by CTU Bern. Original study forms will be entered and 
kept on file at each participating study site. Only system 
administrators will have direct access to the server. For 
quality control of the study conduct and data retrieval, all 
study sites will be visited on-site by appropriately trained 
and qualified monitors of CTU Bern. Data management 
and monitoring works independently from study investi-
gators. All principal investigators will be given access to 
the cleaned datasets.
study duration
We plan to recruit participants over a period of about 
2 years. Once recruited, participants will be followed-up 
for 1 year.
Sample size
Sample size calculation was done using Stata Statistical 
Software and the clustersampsi command V.st0286 2.35 We 
estimated that the event rate of experiencing at least one 
DRA over a 12-month follow-up (primary endpoint) is 
~20% in the control group.15 36 We assumed that patient 
deaths and drop-outs would be increasing during the 
follow-up phase and that the DRA event rate would slightly 
decrease over time. Combining these assumptions with 
an overall mortality of 20%37 and a drop-out rate of 6% 
both at 1 year, we estimated the event rate in the control 
group at 19.5%. We aimed to detect a 30% relative risk 
reduction by the intervention at a two-sided alpha of 5%, 
assuming an intracluster correlation of 0.02 as typically 
found for binary outcomes in elderly individuals.38
This translates into an expected DRA event rate of 13.7% 
in the intervention group. We also performed a survey at 
all trial sites to realistically estimate the number of avail-
able clusters. All sites responded and the overall number 
of clusters available for the trial was estimated at ~80. The 
same survey revealed that a cluster size of 25 participants 
would be realistic but that this might vary from cluster to 
cluster. We therefore allowed for variable cluster size with 
a coefficient of variation of 0.25 (effectively allowing for a 
cluster size ranging from 12 to 38 participants). Based on 
these assumptions, 2000 patients, 1000 patients in each 
arm, need to be recruited over 24 months in order to 
have 80% power in order to show a statistically significant 
difference for the primary endpoint.
statistical analysis
All statistical analyses including a description of all rele-
vant derivations of variables will be described in a statis-
tical analysis plan before the end of recruitment and 
without inspection of the data. A statistician at CTU Bern 
will perform the statistical analyses using R Statistical 
Software.39
In the primary analysis, all patients will be analysed 
using the FAS (full analysis set) according to the intention-
to-treat principle. The primary outcome, first confirmed 
DRA after discharge, will be analysed by using a mixed-ef-
fects survival model with a fixed effect for the intervention 
group and random-effects for centre and treating physi-
cian to account for clustering. To deal with competing 
risks (ie, death as competing risk for DRA), we will use 
extensions of the Fine-Gray proportional hazards model 
that account for clustering in competing risk settings.
Secondary time-to-event outcomes will be analysed 
using Kaplan-Meier curves and a mixed-effects Cox 
proportional hazards model with a fixed effect for the 
intervention group and random effects for centre and 
treating physician. Binary outcomes will be analysed using 
a mixed-effects logistic regression model using a fixed 
effect for the intervention group and random effects for 
centre and treating physician. Continuous outcomes will 
be analysed using mixed-effects linear model with a fixed 
effect for the intervention group and random effects for 
centre and treating physician, adjusted for the baseline 
value as a covariate if available.
To deal with dropouts and losses to follow-up (expected 
to be mainly caused by death), we will employ two different 
strategies: in the first approach, we will impute missing 
data. In the second approach, we will explore whether 
data allow for joint modelling of repeated measures and 
survival data.
In a secondary per-protocol (PP) analysis, all outcomes 
will be evaluated as described above based on the PP anal-
ysis set. Since cluster randomisation may lack the excel-
lent balancing in characteristics between groups seen in 
individual-level randomisation, we will also adjust each 
model for additional patient-level, physician-level and 
hospital-level variables in a sensitivity analysis.
Ethics and dissemination
The local ethics committee at each site has approved the 
study protocol and other documentation concerning the 
study conduct. Where needed, approval by a regulatory 
authority has been obtained before enrolment of the 
first patient. All participants and their data are handled 
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according to the ethical principles of the Declaration of 
Helsinki.40 This study complies with all applicable stan-
dards of the International Conference on Harmonisa-
tion E6 Guideline for Good Clinical Practice (ICH-GCP 
1996) guideline.41 The ethics committees and regula-
tory authorities receive annual safety reports and will be 
informed about study stop/end in agreement with local 
requirements. OPERAM embraces an open access policy 
and strives for complete dissemination of all resulting 
data, clinical results and publications.
Patient and public involvement
A patient organisation was involved in the trial design and 
the development of the research question and the choice 
and measure of the outcomes (WHO Patients for Patient 
Safety Advocate Group; http://www. who. int/ patientsafety/ 
patients_ for_ patient/ en/), as well as in the conduct of the 
study by being member of the scientific advisory board. 
Patients were actively involved in several steps of the process 
of developing the core outcome sets. Specifically, semistruc-
tured interviews with older patients and caregivers were 
undertaken in order to identify the most relevant outcomes 
for older individuals and stakeholders.42 To limit the burden 
of the intervention, special adaptations were planned for 
very old and sick patients (printable versions of the question-
naires, filling the questionnaire with an interviewer, priority 
lists to reduce the burden of the intervention) based on 
pilot patients and first patients enrolled, as well as specific 
processes for patients with of cognitive impairment, with 
the support of their relatives. Patients have no role in the 
recruitment of study participants, but are actively involved 
in the study intervention through shared decision-making. 
The results of this study will be disseminated to the patients 
through newsletters and through the above-mentioned 
patient organisation.
dIsCussIon
This is the first large multicentre randomised trial that 
examines the impact of a structured approach to opti-
mising pharmacotherapy in hospitalised multimorbid 
older individuals on clinical outcomes, including DRAs, 
inappropriate medication use and QoL. It will also be one 
of the largest trials in the growing population of multi-
morbid older adults that are currently understudied, 
as they are often excluded from trials due to their age 
and multimorbidity1; as a result, clinical guidelines are 
based on evidence that might not relate to patients with 
multimorbidity, underlining the need of this trial among 
elderly patients with multimorbidity.
The above described trial has several important 
strengths: it is a multicentre, large trial with broad inclu-
sion criteria and very few exclusion criteria in order to 
provide good external validity. Patients with cognitive 
impairment will not be excluded, as this population 
is particularly prone to polypharmacy and its negative 
consequences and may particularly benefit from medi-
cation optimisation.43 The studied intervention is well 
defined with clear steps. The primary outcome (DRA) is 
adjudicated according to well defined standard operating 
procedures by an adjudication committee consisting of 
experienced physicians and pharmacists.
Limitations to this trial are the cluster randomised 
design, which was chosen to avoid a learning effect of 
the prescribing physicians allocated to the control group. 
However, this design is susceptible to selection bias, which 
we will try to avoid through measures summarised below. 
Finally, the outcome assessment at follow-up is based on 
the patient’s or proxy’s self-report and might therefore 
miss some events. In this cohort of multimorbid older 
patients, the death rate is expected to be high and we will 
have to account for death in our analyses.
Potential problems and solutions
To avoid possible selection bias, we aim to keep the study 
personnel as blinded as possible. Due to the nature of 
the intervention, complete blinding of all the study staff 
(eg, the staff conducting the intervention) is not possible. 
However, recruiting study staff and outcome assessors are 
kept blinded as to the randomisation status of patients, 
at all times. Study source data with unblinding potential 
are stored in a secure place without investigator access. 
Patients are kept partially blinded from the allocation of 
their prescribing physician (table 2). All patients included 
in the study control arm undergo a sham intervention in 
order to mimic the procedure of the intervention arm.
Outcome assessors are blinded concerning the patient’s 
study group allocation. Adjudication is carried out based 
on completely anonymised information about deaths 
and rehospitalisations acquired by the unblinded study 
personnel. Due to legal regulations and language issues 
(hospital reports and follow-up notes during hospitalisa-
tions are in the local language), a central data adjudica-
tion is not possible. However, we cross-reference a limited 
number of events in a central manner in order to avoid 
site-specific bias.
In order to avoid bias from cluster contamination, 
clusters are temporarily closed in case of absence of the 
prescribing physician. There is the potential of contam-
ination at the level of a patient’s GP; however, we used 
partial blinding of GPs who receive only standardised 
high-level information about the study goals. Also, the 
number of GPs with patients in both the intervention 
and control group is expected to be small, given that the 
number of GPs referring patients to the enrolling leading 
university leading centres is very large.
To assess the potential for selection of a specific subpop-
ulation into the trial and better understand generalis-
ability of the study results, we will compare differences 
in selected characteristics such as age and gender of 
consenting and non-consenting patients.
ConClusIon
The cluster-randomised OPERAM trial aims to add to 
provide direct evidence of best care for the growing 
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population of older and multimorbid persons among the 
wider European population. The trial exclusively includes 
patients aged ≥70 years with multimorbidity for whom few 
direct comparisons of pharmacotherapy strategies exist. 
In the long term, we hope to contribute to an improved 
health status for the rapidly growing older population 
with multimorbidity and polypharmacy.
Current status of the oPErAM trial
The OPERAM trial started recruitment in December 
2016. The trial follow-up will be completed in the 2nd 
semester of 2019.
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